High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
Protein & Cell
; (12): 877-888, 2021.
Article
em En
| WPRIM
| ID: wpr-922482
Biblioteca responsável:
WPRO
ABSTRACT
A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak. Currently, effective treatment options remain very limited for this disease; therefore, there is an urgent need to identify new anti-COVID-19 agents. In this study, we screened over 6,000 compounds that included approved drugs, drug candidates in clinical trials, and pharmacologically active compounds to identify leads that target the SARS-CoV-2 papain-like protease (PLpro). Together with main protease (M
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Antivirais
/
Inibidores de Proteases
/
Sítios de Ligação
/
Proteínas Recombinantes
/
Mutagênese Sítio-Dirigida
/
Naftoquinonas
/
Estrutura Terciária de Proteína
/
Cristalografia por Raios X
/
Concentração Inibidora 50
/
Avaliação Pré-Clínica de Medicamentos
Tipo de estudo:
Diagnostic_studies
/
Screening_studies
Limite:
Humans
Idioma:
En
Revista:
Protein & Cell
Ano de publicação:
2021
Tipo de documento:
Article
